# Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Source: https://onco.cc/trials/nct05447702/  
OnCo record `nct05447702` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of camrelizumab, rivoceranib (apatinib), nab-paclitaxel, epirubicin and other drugs in triple-negative breast cancer, run by West China Hospital, now recruiting.

## Summary

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) is a phase 2, interventional study registered as NCT05447702 by West China Hospital, with a registry enrolment figure of 35 participants, started 2022-11-01 and due to reach its primary completion in 2023-12-31. Interventions recorded: Camrelizumab; Apatinib; Nab-paclitaxel; Epirubicin; Cyclophosphamide. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Early or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05447702
- Phase: 2
- Setting: A Single-arm, Prospective Phase II Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC)
- Sponsor: West China Hospital
- Enrolled: 35

## Sources

- ClinicalTrials.gov NCT05447702: https://clinicaltrials.gov/study/NCT05447702

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Epirubicin](https://onco.cc/drugs/epirubicin/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Rivoceranib (apatinib)](https://onco.cc/drugs/rivoceranib/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05447702.json